BioMérieux Spotlights Diagnostic Solutions in Use of Antibiotics
|
By LabMedica International staff writers Posted on 07 Aug 2019 |

Image: The Bact/Alert Virtuo diagnostic solution (Photo courtesy of BioMérieux).
BioMérieux (Marcy-l'Étoile, France) showcased its unique and comprehensive range of diagnostic solutions that support the responsible use of antibiotics to improve patient care at AACC 2019. Among its diagnostic solutions highlighted at the tradeshow was Bact/Alert Virtuo, which along with bioMérieux’s Bact/Alert Virtuo blood culture system and Bact/Alert Fan Plus media, provides fast and actionable results for better antimicrobial stewardship.
BioMérieux showcased its Vitek 2 automated system consisting of instruments, software, and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The company also highlighted its Advanced Expert System (AES), which analyzes MIC patterns and detects resistance phenotypes for most organisms tested. Also showcased at the event was bioMérieux’s Vitek MS mass spectrometry microbial identification system that uses MALDI-TOF technology and contains a comprehensive database FDA 510(k) cleared for 401 organisms with 1,316 total organisms to provide highly-accurate identifications.
At AACC 2019, bioMérieux showcased the Vidas 3 fully automated benchtop immunoassay system based on the proven ELFA technology, for specialty testing at the fingertips. Vidas 3 features Vidas B•R•A•H•M•S PCT, which is FDA-cleared to aid in decision-making on antibiotic therapy for patients with sepsis and patients with suspected or confirmed lower respiratory tract infections (LRTI). Other solutions showcased at the event included the Nephrocheck test to gauge the risk of acute kidney injury (AKI) and intervene before damage occurs and the MYLA software which provides a real-time, control-tower overview for blood culture, identification, and antimicrobial susceptibility with flexible, easy-to-generate reports, offering flexible data insights to help drive proactive antimicrobial stewardship and optimal patient management.
BioMérieux also highlighted its AGILIST advanced analytic platform which securely connects and integrates siloed systems into a single source focused on operational efficiency, antimicrobial stewardship and surveillance, analyzing data in real-time, addressing problems, providing reliable information, and improving communications among key stakeholders. Additionally, bioMérieux showcased the PhenoMATRIX for WASPLab that allows labs to take their automated processes to the next level by utilizing artificial intelligence and interpretative algorithms for sample interpretation and automated sorting. PhenoMATRIX evaluates growth on a media plate through user-defined custom rules, allowing staff to spend less time reading plates and focus on those that are positive.
BioMérieux showcased its Vitek 2 automated system consisting of instruments, software, and reagent cards designed for the identification and antimicrobial susceptibility testing of bacteria and yeast. The company also highlighted its Advanced Expert System (AES), which analyzes MIC patterns and detects resistance phenotypes for most organisms tested. Also showcased at the event was bioMérieux’s Vitek MS mass spectrometry microbial identification system that uses MALDI-TOF technology and contains a comprehensive database FDA 510(k) cleared for 401 organisms with 1,316 total organisms to provide highly-accurate identifications.
At AACC 2019, bioMérieux showcased the Vidas 3 fully automated benchtop immunoassay system based on the proven ELFA technology, for specialty testing at the fingertips. Vidas 3 features Vidas B•R•A•H•M•S PCT, which is FDA-cleared to aid in decision-making on antibiotic therapy for patients with sepsis and patients with suspected or confirmed lower respiratory tract infections (LRTI). Other solutions showcased at the event included the Nephrocheck test to gauge the risk of acute kidney injury (AKI) and intervene before damage occurs and the MYLA software which provides a real-time, control-tower overview for blood culture, identification, and antimicrobial susceptibility with flexible, easy-to-generate reports, offering flexible data insights to help drive proactive antimicrobial stewardship and optimal patient management.
BioMérieux also highlighted its AGILIST advanced analytic platform which securely connects and integrates siloed systems into a single source focused on operational efficiency, antimicrobial stewardship and surveillance, analyzing data in real-time, addressing problems, providing reliable information, and improving communications among key stakeholders. Additionally, bioMérieux showcased the PhenoMATRIX for WASPLab that allows labs to take their automated processes to the next level by utilizing artificial intelligence and interpretative algorithms for sample interpretation and automated sorting. PhenoMATRIX evaluates growth on a media plate through user-defined custom rules, allowing staff to spend less time reading plates and focus on those that are positive.
Latest AACC 2019 News
- Instrumentation Laboratory Presents New IVD Testing System
- Quidel Welcomes Newest Member of Triage Family
- ERBA Mannheim Unveils Next-Generation Automation
- Roche Demonstrates How Health Networks Are Driving Change in Labs and Beyond
- Thermo Shows New Clinical Innovations
- Randox Launches New Innovations
- Streck Introduces Three New Antibiotic Resistance Detection Kits
- EKF Diagnostics Highlights Assay for Diabetes Patient Monitoring
- Sysmex America Exhibits New Products, Automation and Quality Solutions
- BBI Solutions Showcases Mobile Solutions Capabilities at AACC 2019
- MedTest Dx Releases New Product Line for Drugs of Abuse Testing
- Mesa Biotech Launches Molecular Test System at AACC 2019
- Ortho Clinical Diagnostics Highlights Groundbreaking Lab Technology
- Abbott Diagnostics Exhibits POC Diagnostics Solutions at AACC
- Beckman Coulter Demonstrates Latest Innovations in Lab Medicine
- Orion Diagnostica Showcases Range of Products in Anaheim
Channels
Clinical Chemistry
view channel
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
Many cancers deviate from the normal chromosome number, but the clinical impact of extreme chromosome loss remains unclear. This widespread genomic disruption is associated with aggressive disease and... Read more
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read more
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel









